| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
1 | 28 | 0 | 651 | 0 |
| Cost of Revenue
|
-- | -- | -- | -- | -2,591 |
|
Gross Profit
|
-- | -- | -- | -- | -820 |
|
Selling, General and Administrative Expenses
|
-8,044 | -7,479 | -8,534 | -11,994 | -17,011 |
|
Research and Development Expenses
|
-6,704 | -6,033 | -6,718 | -5,546 | -3,341 |
|
Operating Income/Expenses
|
-14,748 | -13,512 | -15,252 | -17,540 | -20,352 |
|
Total Operating Profit/Loss
|
-14,747 | -13,484 | -15,252 | -16,889 | -20,352 |
| Total Net Finance Income/Expense
|
625 | 436 | 285 | 1,282 | 386 |
| Net Investment Income
|
-954 | -1,315 | 1,963 | 5,320 | -- |
| Irregular Income/Expenses
|
-- | -- | -- | 0 | 79,104 |
|
Non-Operating Income/Expenses, Total
|
-329 | -879 | 2,248 | 6,602 | 79,490 |
|
Pretax Income
|
-15,076 | -14,363 | -13,004 | -10,287 | 59,138 |
|
Provision for Income Tax
|
-- | -- | -- | 0 | -13 |
|
Net Income from Continuing Operations
|
-15,076 | -14,363 | -13,004 | -10,287 | 59,125 |
|
Discontinued Operations
|
0 | 73 | 0 | -8,110 | -11,370 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-15,076 | -14,290 | -13,004 | -18,397 | 47,755 |
|
Net Income after Non-Controlling/Minority Interests
|
-15,076 | -14,290 | -13,004 | -18,397 | 47,755 |
| Preferred/Other Stock Distribution
|
-- | -- | -- | 0 | -5,426 |
|
Net Income Available to Common Stockholders
|
-15,076 | -14,290 | -13,004 | -18,397 | 42,329 |
|
Diluted Net Income Available to Common Stockholders
|
-15,076 | -14,290 | -13,004 | -18,397 | 42,342 |
| Basic EPS
|
-0.26 | -0.34 | -0.50 | -1.29 | 5.73 |
| Diluted EPS
|
-0.26 | -0.34 | -0.50 | -1.29 | 5.72 |
|
Basic Weighted Average Shares Outstanding
|
63,544.6560 | 42,410.7110 | 25,845.6390 | 14,263.7440 | 7,385.3480 |
|
Diluted Weighted Average Shares Outstanding
|
63,544.6560 | 42,410.7110 | 25,845.6390 | 14,263.7440 | 7,406.9860 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-15,701 | -14,799 | -13,289 | -11,569 | 58,752 |
|
EBITDA
|
-15,701 | -14,799 | -13,289 | -11,258 | 60,399 |
|
Normalized EBITDA
|
-13,953 | -12,785 | -13,017 | -7,331 | -15,041 |
|
Normalized Income
|
-13,328 | -12,349 | -12,732 | -6,360 | -16,298.4032 |
|
Total Unusual Items
|
1,748 | 2,014 | 272 | 3,927 | -75,440 |
12/31/2022 - 2/11/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade